CLL Advocates Network

The CLL Advocates Network (CLLAN) is the global network of chronic lymphocytic leukaemia (CLL) patient groups. It was founded in 2014 by representatives from Canada, Czech Republic, France, Ireland, Italy, Portugal, UK and the United States. As a global network, the CLL Advocates Network’s mission is to enhance CLL patient care and improve patients’ outcomes.

The following principles guide CLLAN’s work:

  • Act as an international collective representative of CLL patient advocates
  • Develop tools to empower advocates to support their local CLL communities
  • Share best practices
  • Advocate for better care and access
  • Aid in the development of CLL specific support in all countries

The CLL Advocates Network hosts “CLL Horizons”, its annual conference designed to build capacity in patient advocates, to educate them and grow their skills on how to work locally with their patient groups, in good governance, in disease-specific topics, and to create an opportunity to leverage the network’s experience for the benefit of all CLL patients worldwide.

The CLL Advocates Network is governed by a Steering Committee consisting of the 9 members, of whom 6 are patients and 1 is a carer:

  • Nick York
    Steering Committee Member & Chair, United Kingdom
  • Pierre Aumont
    Steering Committee Member & Vice Chair, France
  • Jana Pelouchova
    Steering Committee Member & Treasurer, Czech Republic
  • Michael Rynne
    Steering Committee Member & Communications Officer, Ireland
  • Felice Bombaci
    Steering Committee Member, Italy
  • Brian Koffman
    Steering Committee Member, United States of America
  • Deborah Baker
    Steering Committee Member, Canada
  • Kathryn Huntley
    Steering Committee Member, Australia
  • Jennifer Wilson
    Steering Committee Member, United States of America

The Steering Committee of the CLL Advocates Network is supported Mirna Tomašević mirna@clladvocates.net as Administrative Coordinator.

For more information, please visit the CLL Advocates Network website.